Daratumumab for Polyneuropathy Associated With MGUS
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about daratumumab and hyaluronidase-fihj in
patients with monoclonal gammopathy of undetermined significant (MGUS) who have been
diagnosed with peripheral neuropathy suspected to be cause by paraproteinemia. The main
question[s] it aims to answer are:
• how well does this medication help improve MGUS associated peripheral neuropathy
Participants will be asked be asked to get some testing done prior to starting the trial in
order for us to assess your nerve damage or peripheral neuropathy. This will include blood
tests, a complete neurologic examination, surveys and tests called electromyogram and nerve
conduction studies. Participants that qualify for the trial will take DARZALEX FASPRO® once a
week for two months, followed by every other week from months 3 to month 6.